U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

Ads

You May Also Like

Enzymatica AB: Enzymatica enters into partnership agreement with STADA Arzneimittel AG

Press ReleaseLund February 13, 2017                                                                                    Enzymatica enters into partnership agreement with STADA Arzneimittel AG ...